sCLEC-2 ELISA
- Regulatory Status
- RUO
- Kit size
- 1 x 96 Wells
- Method
- ELISA
- Incubation time
- 1 x 60 min, 1 x 60 min, 1 x 30 min
- Standard range
- 6.25 - 400 pg/mL
- Specimen / Volumes
- 100 μL Citrate Plasma
- Substrate / isotope
- TMB 450 nm
Soluble CLEC-2
CLEC-2 (C-type lectin-like receptor 2) is identified as the receptor for the platelet-activating snake venom, rhodocytin, and is predominantly expressed in platelets and megakaryocytes. It has been implicated in various physiological and pathological processes, including cancer metastasis and thrombosis (Inoue et al., 2019).
Biological Significance of sCLEC-2
Platelets are activated by factors such as collagen and shear stress when the vascular wall is damaged by trauma or inflammation. During this process, membrane-bound CLEC-2 is cleaved by platelet-derived proteases and shed into the bloodstream as soluble CLEC-2 (sCLEC-2). Furthermore, CLEC-2 is also considered to be released in association with platelet-derived microparticles generated during platelet activation, suggesting that sCLEC-2 is present in the circulation in multiple forms, including microparticle-associated forms (Kazama et al., 2015).
Research Findings
It has been reported that blood levels of sCLEC-2 are increased in arterial thrombosis, such as cerebral and myocardial infarction and further studies are warranted (Nishigaki et al., 2021). Citrate plasma is recommended for measurement.
Manufactured by IBL-Japan (Original Ref. Nr. #27820), distributed by Tecan, IBL International GmbH. For concrete data please consult the Instruction for Use in the download box on the top right side.
Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI. Osamu Inoue et al. Int J Hematol. 2019 Sep;110(3):285-294.
Measurement of soluble C-type lectin-like receptor 2 in human plasma. Fuminori Kazama et al. Platelets. 2015;26(8):711-9.
Soluble C-Type Lectin-Like Receptor 2 Elevation in Patients with Acute Cerebral Infarction. Akisato Nishigaki et al. J Clin Med. 2021 Jul 30;10(15):3408.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.